Item 16. FORM 10-K SUMMARY

2K characters. Original on sec.gov · Markdown

Item 16. FORM 10-K SUMMARY

None.

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized.

	BIO-TECHNE CORPORATION


Date: August 25, 2021		/s/ Charles Kummeth
		By: Charles Kummeth
		Its: President and CEO

Pursuant to the requirements of the Securities Exchange Act of 1934, this Report has been signed by the following persons on behalf of the Registrant and in the capacities and on the dates indicated.

Date	Signature and Title

August 25, 2021	/s/ Robert V. Baumgartner
	Robert V. Baumgartner
	Chairman of the Board and Director

August 25, 2021	/s/ Julie Bushman
	Julie Bushman, Director

August 25, 2021	/s/ Rupert Vessey
	Dr. Rupert Vessey, Director

August 25, 2021	/s/ Joseph Keegan, Ph.D.
	Dr. Joseph Keegan, Director

August 25, 2021	/s/ John L. Higgins
	John L. Higgins, Director

August 25, 2021	/s/ Roeland Nusse, Ph.D.
	Dr. Roeland Nusse, Director

August 25, 2021	/s/ Alpna Seth, Ph.D.
	Dr. Alpna Seth, Director

August 25, 2021	/s/ Randolph C. Steer, Ph.D., M.D.
	Dr. Randolph C. Steer, Director

August 25, 2021	/s/ Charles Kummeth
	Charles Kummeth, Director and Chief Executive Officer (principal executive officer)

August 25, 2021	/s/ James Hippel
	James Hippel, Chief Financial Officer
	(principal financial officer and principal accounting officer)

Previous: Cover and table of contents